Dai Li
- Cancer Research top 10%
- Cancer-related molecular mechanisms research 9
- Pharmacology top 5%
- Molecular Biology top 10%
- RNA modifications and cancer 6
- Natural product bioactivities and synthesis 4
- Biological Activity of Diterpenoids and Biflavonoids 4
- Epigenetics and DNA Methylation 4
- Immunology top 10%
-
- Ferroptosis and cancer prognosis 9
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 7
- Pulmonary Hypertension Research and Treatments 5
- Co-authors
- Qi LiFan WuYuanyuan JingRong LiJiang Ting-liangHai-Ru HuoYun‐Peng SuiHaiyu Zhou
- Journals
- European Journal of Pharmacology (5 papers)Canadian Journal of Physiology and Pharmacology (4 papers)International Immunopharmacology (4 papers)
- Partner nations
- ChinaUnited StatesJapan
In The Last Decade
Dai Li
100 papers receiving 1.9k citations
Peers
Comparison fields: 5 of 125
- Cancer Research 284
- Pharmacology 298
- Molecular Biology 982
- Immunology 233
- Complementary and alternative medicine 87
Countries citing papers authored by Dai Li
This map shows the geographic impact of Dai Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dai Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dai Li more than expected).
Fields of papers citing papers by Dai Li
This network shows the impact of papers produced by Dai Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dai Li. The network helps show where Dai Li may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Dai Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2024 | 17 | |
| 3 | 2024 | 5 | |
| 4 | 2024 | 5 | |
| 5 | 2024 | 4 | |
| 6 | 2024 | 3 | |
| 7 | 2023 | 6 | |
| 8 | 2023 | 8 | |
| 9 | 2020 | 9 | |
| 10 | 2019 | 54 | |
| 11 | 2017 | 66 | |
| 12 | 2017 | 30 | |
| 13 | 2016 | 1 | |
| 14 | 2016 | 15 | |
| 15 | The role of CGRP and CALCA T-692C single-nucleotide polymorphism in psoriasis vulgaris. | 2015 | 11 |
| 16 | 2015 | 15 | |
| 17 | 2013 | 28 | |
| 18 | 2012 | 1 | |
| 19 | Deletion of tumor suppressor P53gene in diffuse large B-cell lymphoma with heterogeneous immunophenotype | 2012 | 1 |
| 20 | Progress of the interaction between small--molecules and deoxyribonucleic acid | 2005 | 1 |
About Dai Li
Dai Li is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine, Immunology, Molecular Biology and Pharmacology, having authored 106 papers that have together received 1.9k indexed citations. Recurring topics across this work include Ferroptosis and cancer prognosis (9 papers), Cancer-related molecular mechanisms research (9 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (7 papers), RNA modifications and cancer (6 papers), Pulmonary Hypertension Research and Treatments (5 papers), Natural product bioactivities and synthesis (4 papers), Biological Activity of Diterpenoids and Biflavonoids (4 papers) and Epigenetics and DNA Methylation (4 papers). The work is most often cited by research in Cancer Research (284 citations), Pharmacology (298 citations), Molecular Biology (982 citations), Immunology (233 citations) and Complementary and alternative medicine (87 citations). Dai Li has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Qi Li, Fan Wu, Yuanyuan Jing, Rong Li, Jiang Ting-liang, Hai-Ru Huo, Yun‐Peng Sui, Haiyu Zhou, Weihao Wang and Feng Sui. Their work appears in journals such as European Journal of Pharmacology, Canadian Journal of Physiology and Pharmacology, International Immunopharmacology, Scientific Reports and World Journal of Surgical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.